» Articles » PMID: 23109979

Detection of Survivin and COX-2 in Thyroid Carcinoma: Anaplastic Carcinoma Shows Overexpression of Nuclear Survivin and Low COX-2 Expression

Overview
Journal Korean J Pathol
Specialty Pathology
Date 2012 Oct 31
PMID 23109979
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Overexpression of survivin, a member of the inhibitors of apoptosis protein, has been reported in various carcinomas, and its interaction with cyclooxygenase 2 (COX-2) results in accelerated tumor progression. The purpose of this study is to investigate the immunohistochemical expression of survivin and COX-2 in benign and malignant thyroid tissues and to define its association with pathologic and clinical features.

Methods: We examined expression of survivin and COX-2 by immunohistochemistry in 334 benign and malignant thyroid tissues and evaluated their clinical significance.

Results: Expression of survivin showed an increase along the spectrum of thyroid carcinoma progression; rarely positive in adenomatous goiter, moderately positive in papillary carcinoma, and strongly positive in anaplastic carcinoma (AC). Papillary microcarcinoma revealed the highest COX-2 positivity and AC demonstrated the lowest positivity among thyroid cancers. Node negative carcinomas showed higher COX-2 expression than node positive tumors. Survivin expression did not correlate with COX-2.

Conclusions: Our findings suggest that survivin overexpression may be related to the pathogenesis of AC and can be a predictor of disease progression. COX-2 may be involved in the early phase of thyroid carcinoma.

Citing Articles

TFAP2B overexpression contributes to tumor growth and progression of thyroid cancer through the COX-2 signaling pathway.

Fu X, Zhang H, Chen Z, Yang Z, Shi D, Liu T Cell Death Dis. 2019; 10(6):397.

PMID: 31113934 PMC: 6529436. DOI: 10.1038/s41419-019-1600-7.


Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma.

Perisa M, Sarcevic B, Gall Troselj K, Grsic K, Sitic S, Seiwerth S Oncol Lett. 2017; 13(5):3547-3555.

PMID: 28521457 PMC: 5431143. DOI: 10.3892/ol.2017.5876.


The Diagnostic Usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 δ in Follicular Thyroid Carcinoma.

Jang M, Jung K, Min H J Pathol Transl Med. 2015; 49(2):112-7.

PMID: 25812733 PMC: 4367106. DOI: 10.4132/jptm.2015.01.31.

References
1.
Ambrosini G, Adida C, Sirugo G, Altieri D . Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998; 273(18):11177-82. DOI: 10.1074/jbc.273.18.11177. View

2.
Dohi T, Beltrami E, Wall N, Plescia J, Altieri D . Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 2004; 114(8):1117-27. PMC: 522254. DOI: 10.1172/JCI22222. View

3.
Ito Y, Yoshida H, Uruno T, Nakano K, Miya A, Kobayashi K . Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma. Oncol Rep. 2003; 10(5):1337-40. View

4.
Kleinschmidt-DeMasters B, Heinz D, McCarthy P, Bobak J, Lillehei K, Shroyer A . Survivin in glioblastomas. Protein and messenger RNA expression and comparison with telomerase levels. Arch Pathol Lab Med. 2003; 127(7):826-33. DOI: 10.5858/2003-127-826-SIG. View

5.
Erkanli S, Bolat F, kayaselCuk F, Demirhan B, Kuscu E . COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol. 2006; 104(2):320-5. DOI: 10.1016/j.ygyno.2006.08.044. View